2020 Agenda


  • Day One includes the following topics:

    • Discovery/Preclinical Science 
    • Imaging Aspects 
    • Clinical Operations 
    • Next Generation Bispecifics
  • 7:30 am

  • Registration

  • 8:15 am

  • Co-Chair's Opening Remarks


    Axel Hoos, MD, PhD

    SVP, Therapeutic Area Head, Oncology R&D, GSK


    James Gulley, MD, PhD

    Chief, Genitourinary Malignancies Branch, Director, Medical Oncology Service, Center for Cancer Research, National Cancer Institute, NIH

  • 8:25 am

  • Opening Keynote: CRISPR Engineering with T-Cells


    Carl June, MD

    Richard W. Vague Professor in Immunotherapy at the Department of Pathology and Laboratory Medicine; Director, Center for Cellular Immunotherapies at the Perelman School of Medicine; Director, Parker Institute for Cancer Immunotherapy, University of Pennsylvania


  • Discovery/Preclinical Science Plenary Session

    Chaired by:


    James Gulley, MD, PhD

    Chief, Genitourinary Malignancies Branch, Director, Medical Oncology Service, Center for Cancer Research, National Cancer Institute, NIH

  • 8:50 am

  • PD1-IL2v: A Next Generation, Targeted IL-2R Agonist for Cancer Immunotherapy

    Pablo Umaña
    Pablo Umaña, PhD

    Head, Cancer Immunotherapy Discovery, Pharma Research and Early Development, Roche

  • 9:10 am

  • TGF-beta in Cancer: Therapeutic Implications and Opportunities

    Increased TGF-beta signaling in carcinomas promotes cancer progression, through direct effects on the cancer cells as well as on cells of the tumor micro-environment, most notably on immune cells, stromal fibroblasts and endothelial cells. Increased TGF-beta expression, activation and signaling correlate with attenuation or lack of therapeutic responses to anti-PD1/PDL1 antibodies, and are likely to confer a general yet substantial impediment to success of immunotherapies. Hence, combining therapeutic anti-TGF-beta approaches with  anti-PD1/PDL1 therapy is now seen as a highly promising avenue to enhance therapeutic efficacy. However, treatment-related adverse effects of systemic TGF-beta inhibition may impose limitations on such therapeutic combinations, and need to be addressed. These observations raise the question whether more selective approaches should be pursued in limiting or preventing the adverse effects of TGF-beta inhibition in cancer immunotherapy.


    Rik Derynck, PhD

    Professor, Departments of Cell/Tissue Biology and Anatomy, University of California San Francisco

  • 9:30 am

  • Grand Opening of the Networking Café & Exhibit Rooms

    • Breakfast
    • Partnering Tables
    • Meet the Exhibitors
    • Networking
  • 10:15 am

  • Potency-Reduced and PD1-Targeted IL15s for Improve Therapeutic Index

    John Desjarlais
    John Desjarlais, PhD
    SVP, Research & CSO, Xencor

  • 10:35 am

  • Off-the-Shelf Cell-based Cancer Immunotherapy for Mass Production of Precisely Engineered Allogeneic T-Cell and NK Cell Products Derived from (iPSC) Master Cell Lines

    This talk will discuss and outline the roadmap for development of off-the-shelf cell therapies based on engineered T cells and natural killer (NK) cells derived from induced pluripotent stem cell (iPSC) master cell lines. The presentation will highlight single cell engineering for precise editing of unique genetic input, creation of clonal master cell banks for the renewable source of consistent and low-cost large scale manufacturing, and the anti-tumor efficacy of engineered T and NK cells designed with unique attributes to improve safety and potency.

    Valamehr
    Bahram (Bob) Valamehr, PhD

    Chief Development Officer, Fate Therapeutics

  • 10:50 am

  • Harnessing the Potential of NHS-IL-12 for Immunotherapy Combinations

    Sofia Gameiro
    Sofia Gameiro, PhD

    Staff Scientist & Head, Immunomodulation Group, Laboratory of Tumor Immunology and Biology, National Cancer Institute

  • 11:10 am

  • Immune Landscape Signatures for Tumor Microenvironment Characterization and Therapy Response

    Patrick Hurban
    Patrick Hurban, PhD
    Senior Director and Global Head of Translational Genomics, Q² Solutions

  • 11:25 am

  • Neoantigen Vaccine Processing and Algorithms for Predicting Peptide Structure


    Roman Yelensky, PhD

    EVP & Chief Technology Officer, Gritstone Oncology

  • 11:45 am

  • Development of ONCR-177: Armed Oncolytic HSV-1 for Potent and Systemic Stimulation of Antitumor Immunity

    Christophe Quéva
    Christophe Quéva, PhD

    CSO & SVP, Research, Oncorus

  • 12:05 pm

  • Lunch & Partnering Meetings

  • 1:05 pm
    - 3:35 pm

  • Track Choices

    • TRACK A

      Imaging Aspects

      Chaired by:

      Annette Schmidt
      Annette Schmid, PhD

      Senior Scientific Director in Quantitative Translational Sciences- Imaging, Takeda Pharmaceuticals

      1:05 pm

      Comparison of Assessments Using RECIST and irRECIST, and Association with Overall Survival, in 1,765 Patients with Advanced Solid Tumors Treated with Avelumab Monotherapy


      S. Peter Eggleton, MD, FFPM

      Medical Director, GCDC Oncology, Merck KGaA


      1:25 pm

      IO Criteria in the Brain

      This talk will discuss the immunotherapy response assessment for neuro-oncology (iRANO) criteria, pros and cons along with case studies and examples.

      Bohnsack_Oliver
      Oliver Bohnsack, MD, PhD

      VP, Scientific and Medical Services, Medical Imaging, Head of Oncology, Parexel


      Manuela Lesch

      Director, Scientific and Medical Services, Parexel Informatics


      1:45 pm

      Using Technology to Address Challenges in Implementation & Monitoring of IO Criteria

      Amit Vasanji
      Amit Vasanji, PhD

      Chief Technology Officer, Oncology, ERT


      2:00 pm

      New Imaging Technologies for Evaluation of Immune Response 

      Ron Korn
      Ron Korn, MD, PhD

      Founder, Chairman and CMO, Imaging Endpoints


      2:20 pm

      Quantitative Imaging Biomarkers Associated with Patient Outcome in IO


      Laurent Dercle, MD, PhD

      Associate Research Scientist, Columbia University Medical Center


      2:40 pm

      Understanding Predictors of Immune Therapy Response via Tumor Size Dynamic Modeling

      Dean Bottino
      Dean Bottino, PhD

      Senior Scientific Director, Clinical Translational Modeling & Simulation Leader, Takeda


      3:00 pm

      Panel: Innovations & Novel Approaches in IO Imaging & Assessing Responses 

      Moderated by:

      Annette Schmidt
      Annette Schmid, PhD

      Senior Scientific Director in Quantitative Translational Sciences- Imaging, Takeda Pharmaceuticals

      Panelists:

      Gregory Goldmacher
      Gregory Goldmacher, MD, PhD

      Executive Director, Translational Biomarkers, Head of Clinical Imaging, Merck


      S. Peter Eggleton, MD, FFPM

      Medical Director, GCDC Oncology, Merck KGaA

      Ron Korn
      Ron Korn, MD, PhD

      Founder, Chairman and CMO, Imaging Endpoints

      Matt-Silva
      Matthew Silva, PhD

      CEO, Invicro

    • TRACK B

      Clinical Operations

      Chaired by:

      Millie Shultz
      Millie Shultz

      Senior Director, Regional Clinical Trial Operations, Seattle Genetics

      1:05 pm

      Operational Dynamics of Implementing & Managing Basket Trials

      • What are the operational complexities of basket trials? How do they differ from standard IO trials?
      • How do you identify the right institutions who can handle basket trials? What goes into that decision making?
      • How do you set up your protocol in an open ended way so that you can add a cohort or make adjustments based on signals you received?
      • How do you set up your database to be able to manage all the different tumor types and different types of case port forms.

      Millie Shultz
      Millie Shultz

      Senior Director, Regional Clinical Trial Operations, Seattle Genetics


       

      1:30 pm

      CRO Perspective on Operationalizing IO Studies

      • Addressing the unique operational needs of IO studies
      • Embracing innovation to accelerate IO drug development
      • Evolving operational approaches to keep pace with IO science


      Jim Wise
      Executive Director & Head of Center for Immuno-oncology, Cellular, and Gene Therapy, PRA Health Sciences


       

      1:55 pm

      Operational Strategy in T-Cell Engagers / Bispecific Studies 

      • Clinical Trial Design 
      • Landscape, Feasibility & Recruitment 
      • Managing toxicities in Bispecifics
      • Challenges & Opportunities

      Iris Sison
      Iris Sison

      Director, Head of Clinical Operations, IGM Biosciences


       

      2:20 pm

      Panel: How Can Sites, Sponsors and Patients Work Together to Enable Optimal Oncology Drug Development?

      Moderated by:

      Andy Lee
      Andy Lee

      SVP, Head of Global Clinical Trial Operations, Merck

      Panelists:

      Gani Chico
      Isagani (Gani) M Chico, MD

      Senior Director, Clinical Development Services, Covance

      Sheila Diamond
      Sheila Diamond
      Scientific Business Development, Acorn AI, a Medidata company

      laura evans
      Laura Evans Manatos

      Media Specialist, Lazarex Cancer Foundation

      Karen May
      Karen May

      Head, Clinical Operations Oncology, BMS


      Archana Sah

      VP & Head, Clinical Operations, Tizona Therapeutics / Chair, Oncology Board, Society for Clinical Research Sites

  • 3:35 pm

  • Afternoon Networking Break


  • Next Generation Bispecifics Plenary Session

    Chaired by:


    Priti Hegde, PhD

    Chief Scientific Officer, Foundation Medicine

  • 4:20 pm

  • Bispecific Antibodies in Cancer Immunotherapy

    • Bispecific Antibodies overview (history, latest developments in Ab engineering, bispecific vs CAR-Ts)
    • An emerging class of immunotherapeutics: CD3x bispecifics in hematologic malignancies
    • A novel platform of costimulatory bispecifics antibodies to enhance the anti-tumor efficacy of existing therapies

    Dimitris Skokos
    Dimitris Skokos, PhD

    Senior Director, Cancer Immunology, Regeneron Pharmaceuticals, Inc

  • 4:40 pm

  • T-Cell Therapeutics to Treat Hematological Malignancies and Solid Tumors

    T-Cell therapeutics have demonstrated clinical benefit in hematological malignancies and there is growing evidence of activity in solid tumors.  This presentation will describe key findings from recent trials along with observations from nonclinical studies that inform on mechanism of action and approaches to address clinically-observed challenges.

    Julie Bailis, PhD
    Director of Research – Inflammation/Oncology, Amgen

  • 5:00 pm

  • Cancer Immunotherapy Debate: Bispecifics vs Cell Therapies

    Moderated by:

    Charles Graeber new
    Charles Graeber

    Award-winning Journalist and Author of The Breakthrough: Immunotherapy and the Race to Cure Cancer

    Participants:


    Carl June, MD

    Richard W. Vague Professor in Immunotherapy at the Department of Pathology and Laboratory Medicine; Director, Center for Cellular Immunotherapies at the Perelman School of Medicine; Director, Parker Institute for Cancer Immunotherapy, University of Pennsylvania

    vs

    Daniel Dan Chen
    Daniel Chen, MD, PhD

    Chief Medical Officer, IGM Biosciences

  • 5:30 pm

  • Next Generation Bispecifics in Solid Tumors

    • What is happening in hematology bispecific programs compared to solid tumor bispecific programs?
    • What do bispecifics look like in solid tumors and what is driving efficacy?
    • Whats hindering efficacy in solid tumors compared to hematology?
    • How can we improve on it?
    • What should we be doing on the next generation bispecifics?

    Moderated by:


    Priti Hegde, PhD

    Chief Scientific Officer, Foundation Medicine

    Panelists:

    Julie Bailis, PhD
    Director of Research – Inflammation/Oncology, Amgen

    Dimitris Skokos
    Dimitris Skokos, PhD

    Senior Director, Cancer Immunology, Regeneron Pharmaceuticals, Inc

    David Schaer
    David Schaer, PhD

    Director, Translational Oncology Lead, Pfizer

    Pablo Umaña
    Pablo Umaña, PhD

    Head, Cancer Immunotherapy Discovery, Pharma Research and Early Development, Roche

  • 6:15 pm

  • End of Day One

2020 Agenda


  • Day Two includes the following topics:

    • Business Developments
    • IO Novel Technologies
    • Translational Science and Biomarkers
    • Cell & Gene Therapy Day
  • 7:45 am

  • Registration, Exhibits & Partnering Meetings

  • 8:30 am

  • Co-Chair's Opening Remarks


    Andrew Baum, MD

    Head of Global Healthcare; Managing Director, Equity Research, Citi

    Raluca Verona
    Raluca Verona, PhD

    Senior Director, Head of Immune Oncology Translational Research, Janssen R&D

  • 8:45 am

  • Keynote: Next Generation CAR T Cells Engineered to Overcome Resistance

    Crystal Mackall
    Crystal Mackall, MD

    Professor of Pediatrics and Medicine; Director, Stanford Center for Cancer Cell Therapy; Director, Parker Institute for Cancer Immunotherapy at Stanford; Associate Director, Stanford Cancer Institute, Stanford University School of Medicine

  • 9:15 am

  • Networking Café, Exhibits & Partnering Meetings

    • Breakfast
    • Partnering Tables
    • Networking
    • Meet the Exhibitors
  • 9:55 am
    - 5:50 pm

  • Choice between Business Developments, Translational Science & Emerging Biomarkers and Cell & Gene Therapy Day

    One day rates are available for Cell & Gene Therapy Day. Please click here for more information.

    • TRACK A

      Business Developments Plenary Session

      Chaired by:


      Andrew Baum, MD

      Head of Global Healthcare; Managing Director, Equity Research, Citi


      9:55 – 10:20 am

      Financial Keynote: Evaluation and Forecast of the IO Space


      Andrew Baum, MD

      Head of Global Healthcare; Managing Director, Equity Research, Citi


      10:20 – 11:05 am

      What Do Next Generation of Immunotherapies Need to Look Like to Move the Needle?

      The frenzy of deals around IO programs and companies has led to what could be referred to as “BD outpacing science.” That might be said too of the combination trials that have displayed varied results, with a few showing clear benefit, some being outright failures and some promising but not definitive signs of efficacy. These results, while not exactly slowing the IO gold rush, have somewhat tempered enthusiasm and perhaps led to a certain maturing in dealmaking, as seen by the shifting to more back-loaded terms. Which is all by way of framing the context of the macroenvironment, which now begs the question of where will the next big shift come from in immunotherapy.

      • Will it be innovative cell therapies, vaccines against neoantigens, or the next wave of oncolytic viruses? 
      • Will it be known targets with better approaches to modulating them like TGF-beta, A2AR/CD73, even CTLA-4? 
      • Will it be novel targets and pathways targeting transcription or hitting new TNF superfamily members, or new approaches to modulate the TME “bad actors” like MDSCs, CAFs, TAMs, TANs and Tregs?

      This panel will tie together discussion on scientific, translational and business development considerations into the latest thinking on strategizing development in IO that will impact collaborations and investment decision making.

      Led by:

      Jeffrey Bockman
      Jeffrey Bockman, PhD

      EVP & Head, Oncology Practice, Cello Health BioConsulting

      Panelists:

      Buell
      Jennifer Buell, PhD

      President & COO, Agenus Bio

      Charles Drake
      Charles Drake, MD, PhD

      Director Genitourinary Oncology Co-Director Immunotherapy Associate Director, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center

      Asthika Goonewardene
      Asthika Goonewardene, MBA

      Managing Director, Senior Biotech Analyst, SunTrust Robinson Humphrey

      Michael King Jr
      Michael King Jr

      Entrepreneur in Residence, Fortress Biotech

      Emmett Schmidt
      Emmett Schmidt, MD, PhD

      Scientific Associate, VP of Clinical Oncology & Lead, External Collaborations Project Team, Merck Research Labs


       

      IO Novel Technologies

      Chaired by:


      Axel Hoos, MD, PhD

      SVP, Therapeutic Area Head, Oncology R&D, GSK

      11:05 – 11:55 am

      This session showcases companies that have technologies and solutions that will help stakeholders in the IO field advance developments that provide treatment for cancer patients.

      Participating Companies:

      Andres A Gutierrez
      Andres A Gutierrez, MD, PhD

      EVP & CMO

      Advaxis

       

      Steven Walker
      Steven Walker, PhD

      Head, Internal Product Development

       
       
       

      Faisal Khurshid
      Faisal Khurshid

      Engagement Director
      &
      Anne-Cherry
      Anne Cherry, PhD

      Director, Strategy & Operations

       
       
       

      Moutih Rafei
      Moutih Rafei, PhD

      Co-founder & CSO

       

       

      Diana Dupont Roettger
      Diana Dupont-Roettger, PhD

      Chief Scientific Alliance Officer

       


       

      Translational Science & Biomarkers

      Chaired by:

      Raluca Verona
      Raluca Verona, PhD

      Senior Director, Head of Immune Oncology Translational Research, Janssen R&D

      11:55 am – 12:15 pm

      Suppressive Cells in the Tumor Microenvironment 

      Charles Drake
      Charles Drake, MD, PhD

      Director Genitourinary Oncology Co-Director Immunotherapy Associate Director, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center


      12:15 – 12:35 pm

      JNJ-4528 is a Differentiated BCMA-Targeted CAR-T Cell Therapy: Translational Update from CARTITUDE-1, an Ongoing Phase 1b/2 Study in Relapsed and/or Refractory Multiple Myeloma

      Enrique Zudaire
      Enrique Zudaire, PhD

      Scientific Director, Immune Oncology Translational Research, Janssen


      12:35 – 1:35 pm

      Lunch & Partnering Meetings


      1:35 – 2:00 pm

      Cancer Immunotherapy Debate: Insitu Vaccinations vs Systemic Neo-Epitope Vaccinations

      Moderated by:

      Asthika Goonewardene
      Asthika Goonewardene, MBA

      Managing Director, Senior Biotech Analyst, SunTrust Robinson Humphrey

      Participants:

      Charles Drake
      Charles Drake, MD, PhD

      Director Genitourinary Oncology Co-Director Immunotherapy Associate Director, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center

      vs

      Karin Jooss
      Karin Jooss, PhD

      EVP, Research & CSO, Gritstone Oncology


      2:00 – 2:20 pm

      New Biomarkers for I-O Efficacy

      Weber_Jeffrey
      Jeff Weber, MD, PhD

      Deputy Director, Perlmutter Cancer Center; Co-Director, Melanoma Program & Head of Experimental Therapeutics, NYU Langone Medical Center


      2:20 – 2:40 pm

      A New Generation of Multidimensional Biomarkers for Immune Composition and Cell State Fueled by RNA Models 

      • Why legacy single-analyte tools have hindered precision medicine
      • How multidimensional models can be built and leveraged for immune profiling; including cell composition, state (e.g. exhaustion), and biomarker discovery
      • Translating tools from the single-laboratory setting to a decentralized model


      Jarret Glasscock, PhD

      CEO, Cofactor Genomics


      2:40 – 3:00 pm

      Comprehensive Immunogenomics to Enable Composite Biomarkers for Immunotherapy Response

      Predicting patient response to immunotherapies requires a robust approach to tumor immunogenomics. By combining highly sensitive, exome-scale DNA and RNA sequencing with advanced analytics, ImmunoID NeXT provides a broad view of the tumor and the immune-related components of the tumor microenvironment from a single sample preparation. In this presentation, we’ll discuss the benefits of this unique, innovative design for immuno-oncology translational research including mastering challenging samples, utilizing optimized algorithms, and obtaining accurate genomic data for identifying novel composite biomarkers.

      Erin_Newburn
      Erin Newburn, PhD

      Associate Director, Field Applications Scientist, Personalis, Inc


      3:00 – 3:20 pm

      Translational Science Driving Combinatorial Strategies

      Chris Boshoff
      Chris Boshoff, FRCP, FMedSci, PhD

      Chief Development Officer, Pfizer Oncology


      3:20 – 3:35 pm

      Spatial Biology on the GeoMx Platform – Unlocking the Next Dimension of IO Therapeutic Target and Biomarker Discovery

      Sarah Warren
      Sarah Warren, PhD

      Sr. Director, Translational Science, NanoString Technologies


      3:35 – 4:15 pm

      Afternoon Networking Break & Partnering Meetings


      4:15 – 4:35 pm

      TMB and PDL1: The Next Chapter

      This talk will briefly review how TMB entered the conversation in IO, followed by a review of recent data on TMB and PD-L1 and their potential implications for next steps in patient treatment and study designs.

      Alexandra Snyder
      Alexandra Snyder, MD

      Head, Translational Oncology / Executive Director, Oncology Early Development, Merck Research Labs


      4:35 – 4:50 pm

      Standardization of NGS for Oncology Trials and Practice–The PGDx elio™ Model 

      The role of NGS testing in informing clinical decisions and enrolling clinical trials has greatly expanded, now including biomarkers like MSI and Tumor Mutational Burden (TMB) for immune therapies. As oncology begins adopting widespread clinical use of NGS, standardization becomes essential. We are developing IVD NGS assays optimized for these complex and comprehensive tumor profiling applications. Our ctDNA and tissue assays are being designed to empower local laboratories, bringing NGS technologies into standard of care for patients worldwide.

      John Simmons
      John Simmons, PhD

      VP, Translational Medicine, Personal Genome Diagnostics

      4:50 – 5:05 pm

      Digital Phenotypes for Safety and Functional Status in IO and Cell Therapy

      Digital monitoring of oncology patients with wearable sensors and mobile technology presents an opportunity to capture >10X more data than traditional measures of performance status. Digital phenotypes created from at-home data have demonstrated utility as a strong dynamic predictor of short term hospitalizations and other serious treatment related adverse events with significant improvements over ECOG, QoL and tumor stage/size. The systematic difference in median OS among patients sharing the same eligibility features highlights that interpretation of PS represents an obvious opportunity for subjectivity and the introduction of selection bias that cannot be confirmed in retrospect as the cause for disparities in trial outcomes. Cell, IO and other targeted therapies present additional safety risks (e.g. cytokine release syndrome, neurotoxicity) that require thoughtful patient stratification prior to infusion and close monitoring post infusion. Digital phenotypes incorporating activity, vital signs and patient contributed data may better characterize these risks.

      Chris Benko
      Chris Benko

      CEO, Koneksa Health


      5:05 – 5:50 pm

      Panel: Mechanisms and Biomarkers of Resistance in the Era of IO Combination Therapy

      Given the number of combination therapies that are ongoing, one of the ways in which one can prioritize combinations is by assessing the translatability of the preclinical biology into the clinic. We do realize there are challenges associated with this including biological translation and challenges with the tools and technologies available for us to assess biology robustly in patients. This panel will discuss where we stand today, identify the key challenges we are facing and explore the opportunities we have to address those gaps.

      Moderated by: 


      Priti Hegde, PhD

      Chief Scientific Officer, Foundation Medicine

      Panelists:

      Tom Davis
      Tom Davis, MD

      Chief Medical Officer, Genocea

      Georgantas Robert
      Robert Georgantas, PhD

      SVP, Research & Translational Science, Biodesix

      Alexandra Snyder
      Alexandra Snyder, MD

      Head, Translational Oncology / Executive Director, Oncology Early Development, Merck Research Labs

      Raluca Verona
      Raluca Verona, PhD

      Senior Director, Head of Immune Oncology Translational Research, Janssen R&D

    • TRACK B

      Cell & Gene Therapy Day

      Chaired by:


      Aiman Shalabi, PharmD

      VP R&D, Cell and Gene Therapies, GSK


      9:55 – 10:40 am

      Landscape and Evolution of the Marketplace

      Led by:

      Brad Loncor
      Brad Loncar

      CEO, Loncar Investments

      Participants:

      Amanda Murphy
      Amanda Murphy

      Managing Director, Biotechnology Research, BTIG

      Vanessa Lucey
      Vanessa Lucey, PhD

      Director, CRI Venture Fund and Clinical Accelerator, Cancer Research Institute

      Janet Lambert
      Janet Lynch Lambert

      CEO, Alliance for Regenerative Medicine


      Adrian McKemey, PhD

      Managing Director and Head of R&D Strategy Solutions, IQVIA


      10:40 – 11:40 am

      Innovation Hour: New Scientific Frontiers in Cell Therapies for Solid Tumors

      Led by:

      Crystal Mackall
      Crystal Mackall, MD

      Professor of Pediatrics and Medicine; Director, Stanford Center for Cancer Cell Therapy; Director, Parker Institute for Cancer Immunotherapy at Stanford; Associate Director, Stanford Cancer Institute, Stanford University School of Medicine

      Participants:

      Naiyer Rizvi
      Naiyer Rizvi, MD

      Price Family Professor of Medicine; Director, Thoracic Oncology; Co-Director, Cancer Immunotherapy, Columbia University Irving Medical Center

      Mark Dudley
      Mark Dudley, PhD

      SVP, Early Stage Development, Adaptimmune

      Cheng Liu
      Cheng Liu, PhD

      Founder & CEO, Eureka Therapeutics

      Gary Menzel
      Garry Menzel, PhD, MBA

      President & CEO, TCR² Therapeutics


       

      Cell Therapy Pivotal Pharma Developments for Solid Tumors

      11:40 am – 12:00 pm

      TILS Targeting Individual Tumor Mutations

      Stephanie Goff
      Stephanie Goff, MD

      Associate Research Physician, Surgery Branch, National Cancer Institute, NIH


      12:00 – 12:15 pm

      Investigating the Power of Tumor Infiltrating Lymphocytes for Treatment of Cancer


      Maria Fardis, PhD

      President and CEO, IOVANCE Biotherapeutics


      12:15 – 12:35 pm

      Update on NY-ESO


      Aiman Shalabi, PharmD

      VP R&D, Cell and Gene Therapies, GSK


      12:35 – 1:35 pm

      Lunch & Partnering Meetings


      1:35 – 1:55 pm

      Current and Future Innovations Toward GMP Manufacturing of CAR and TCR Engineered T-cells

      Paglia_Michael
      Michael Paglia

      VP, CMC Operations, ElevateBio


      1:55 – 2:10 pm

      Evidence-based Accelerators for Early Phase IO Clinical Development  

      How can you use innovation and calculated risk to accelerate development of cell therapies?  In this talk, IQVIA discusses modeling of IO data to develop new types of strategies vs. modeling strategies to develop new types of evidence.  Lessons learned from early cell therapy entrants on finding, recruiting and following the ‘right’ patients will also be presented.


      Chris Learn, PhD

      Senior Therapeutics Strategy Director, Cell and Gene Therapy, IQVIA


      2:10 – 2:25 pm

      High Throughput Identification of Naturally-Occurring TCRs for Cellular Therapeutics

      Sharon Benzeno
      Sharon Benzeno, PhD

      SVP, Drug Discovery, Adaptive Biotechnologies


      2:25 – 2:50 pm

      Cell & Gene Therapy Debate: Centralized vs Decentralized Manufacturing

      Moderated by:

      Paglia_Michael
      Michael Paglia

      VP, CMC Operations, ElevateBio

      Participants:


      Boro Dropulić, PhD

      Chief Science Officer & General Manager, Lentigen

      vs

      Patrick Hanley
      Patrick Hanley, PhD

      Director, GMP for Immunotherapy / Associate Professor, Children’s National Medical Center / George Washington University


      2:50 – 3:35 pm

      Panel: Evolution of Regulatory Policy For Cell/Gene Therapy

      • What are the greatest challenges to the expeditious development of cell and gene therapies at this time? 
      • How does the existing regulatory framework mesh with the current state of development of cell and gene therapy products?
      • What adaptations or adjustments to the regulatory framework that might further advance manufacturing or clinical development of these products?
      • Are there scientific developments coming that will require further adaptation or adjustment to the regulatory framework?

      Moderated by:

      Peter Marks
      Peter Marks, MD, PhD

      Director, Center for Biologics Evaluation and Research (CBER), FDA

      Panelists:


      Jeff Allen, PhD

      President & CEO, Friends of Cancer Research

      Anne Chew
      Anne Chew, PhD

      Executive Deputy Director, Center for Cellular Immunotherapies, University of Pennsylvania

      Alberto Santagostino
      Alberto Santagostino

      SVP, Global Head of Cell & Gene Technologies, Lonza Pharma & Biotech


      3:35 – 4:15 pm

      Afternoon Networking Break & Partnering Meetings


       

      Moving Beyond Pharma: New Collaborative Development Paradigms for Cell Therapies

      4:15 – 4:25 pm

      Master Protocol for Cell/ Gene Therapies and Parker Institutes Efforts/Innovations in Cell Therapy


      Ramy Ibrahim, MD

      Chief Medical Officer and VP, Clinical Development, Parker Institute for Cancer Immunotherapy


      4:25 – 4:35 pm

      Unlocking Trapped Innovation in Cell, Gene Therapy & Regenerative Medicine

      Finer_Mitch
      Mitch Finer, PhD

      CSO, President and Executive Partner, ElevateBio


      4:35 – 4:45 pm

      Cancer Therapy Evaluation Program Innovations in Cell Therapy (CTEP)

      Sharon_Elad
      Elad Sharon, MD

      Senior Investigator, Cancer Therapy Evaluation Program (CTEP), National Cancer Institute


      4:45 – 4:55 pm

      CRI Clinical Accelerator: A Model for Multisector Collaboration

      Jill O'Donnell-Tormey
      Jill O’Donnell-Tormey, PhD

      CEO & Director, Scientific Affairs, Cancer Research Institute (CRI)


      4:55 – 5:25 pm

      Panel: New Collaborative Development Paradigms for Cell Therapies

      Led by:


      Ramy Ibrahim, MD

      Chief Medical Officer and VP, Clinical Development, Parker Institute for Cancer Immunotherapy

      Panelists:

      Finer_Mitch
      Mitch Finer, PhD

      CSO, President and Executive Partner, ElevateBio

      Jill O'Donnell-Tormey
      Jill O’Donnell-Tormey, PhD

      CEO & Director, Scientific Affairs, Cancer Research Institute (CRI) 

      Sharon_Elad
      Elad Sharon, MD

      Senior Investigator, Cancer Therapy Evaluation Program (CTEP), National Cancer Institute


      5:25 – 5:50 pm

      Cell & Gene Therapy Debate: Intrinsic Editing vs Systemic Combination

      Moderated by:


      Ramy Ibrahim, MD

      Chief Medical Officer and VP, Clinical Development, Parker Institute for Cancer Immunotherapy

      Participants:

      Mark O'Hara
      Mark O’Hara, MD

      Assistant Professor of Medicine, University of Pennsylvania

      vs

      Priceman
      Saul Priceman, PhD

      Assistant Professor, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope

       

  • 5:50 pm

  • Annual Networking Reception & Partnering Meetings

2020 Agenda


  • Day Three includes the following topics:

    • AI & Machine Learning
    • IO Clinical Developments
  • 7:45 am

  • Registration, Exhibits Opening & Partnering Meetings

  • 8:15 am

  • Co-Chair's Opening Remarks

    Daniel Dan Chen
    Daniel Chen, MD, PhD

    Chief Medical Officer, IGM Biosciences


    Jacqueline Karmel

    Group Global Scientific Director / Chair, imCORE Executive Committee, Roche

  • 8:25 am

  • VIP Fireside Chat: Ariella Chivil's Immunotherapy Trial Journey

    Moderated by:


    Cindy Geoghegan

    Patient Advocate

    VIP Patient Guest:

    Ariella Chivil
    Ariella Chivil

    Cancer Survivor and Advocate


  • AI & Machine Learning Plenary Session

    Chaired by:

    Daniel Dan Chen
    Daniel Chen, MD, PhD

    Chief Medical Officer, IGM Biosciences

  • 8:55 am

  • AI & Machine Learning in R&D

    This talk will provide an overview of how AI & Machine Learning is being used in drug discovery and development and how it is applicable to the cancer immunotherapy field.

    Lindsay Edwards
    Lindsay Edwards, PhD

    VP, AI/Machine Learning Engineering, GSK

  • 9:15 am

  • Machine Learning for Tumor and Cell Segmentation and Cell Classification within the Tumor Microenvironment

    Machine/Deep learning methods for the analysis of the tumor microenvironment can greatly aid oncological research through the automation of largely manual tasks. Using their proprietary analytics workflow, NeoGenomics presents results for tumor segmentation, cell segmentation and classification for CD8 and PD-L1, and spatial analytics, which will provide attendees with a deeper understanding of the effect that automation has on analytics precision and time-saving, and how it enables the generation of large volumes of data that were not possible just a couple of years ago.


    Máté Levente Nagy, PhD

    Senior Scientist & Technical Lead, Computational Biology, NeoGenomics Laboratories, Inc

  • 9:35 am

  • Opening of the Networking Café & Exhibit Rooms

    • Breakfast
    • Partnering Meetings
    • Networking
    • Meet the Exhibitors
  • 10:20 am

  • Using Machine Learning to Extract Meaningful Insights for Cancer Immunotherapy

    Led by:


    Matthew Albert, MD, PhD

    VP, Immunology & Infectious Diseases, Insitro

    Panelists:

    Lindsay Edwards
    Lindsay Edwards, PhD

    VP, AI/Machine Learning Engineering, GSK

    Thomas Fuchs
    Thomas Fuchs, PhD

    Founder & CSO, Paige.ai

    Stumpe_Martin
    Martin Stumpe, PhD

    SVP, Data Science, Tempus


  • IO Clinical Developments

    Chaired by:


    Jacqueline Karmel

    Group Global Scientific Director / Chair, imCORE Executive Committee, Roche

  • 11:00 am

  • Agonist Abs to TNF Receptor Family Members

    This talk provides a summary of Abs to TNFR family members and their advances to the clinic (OX40, 4-1BB, CD27, GITR and CD40).  In particular, OX40 agonists will be the focus of this talk and their effects on targeting T cells within the tumor microenvironment. Optimal dose and scheduling of OX40 agonists will also be reviewed.


    Andy Weinberg, PhD
    Chief, Laboratory of Basic Immunology at the Robert W. Franz Cancer Research Center, Providence Cancer Center / CSOAgonOx

  • 11:30 am

  • Clinical Development of ICOS Agonist Antibodies


    Axel Hoos, MD, PhD

    SVP, Therapeutic Area Head, Oncology R&D, GSK

  • 11:50 am

  • Clinical Development of Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-beta and PD-L1


    Olaf Christensen, MD

    VP, Head of bintrafusp alfa, Global Development, EMD Serono

  • 12:10 pm

  • Lunch on Own & Partnering Meetings

  • 1:10 pm

  • Pembrolizumab: Foundational in Both Mono- and Combination Cancer Therapies Across Lines of Treatment


    Roy Baynes, MD, PhD

    SVP & Head, Global Clinical Development, Chief Medical Officer, Merck Research Laboratories

  • 1:30 pm

  • Novel Approaches to IO-IO Combinations

    Lee_James
    Lee James, MD, PhD

    Clinical Program Lead, Early Clinical Development, Oncology, BMS

  • 1:50 pm

  • Enhancing Efficacy and Safety of 4-1BB Agonist with Tumor Targeted Bispecifics

    Ingmar Bruns
    Ingmar Bruns, MD, PhD

    Senior Vice President, Head of Clinical Development, Pieris

  • 2:00 pm

  • Clinical Development of First-in-class Innate IO Agents

    Masoud Tavazoie
    Masoud Tavazoie, MD, PhD
    CEO & Co-founder, RGENIX 

  • 2:15 pm

  • HLA Loss and the Impact on Immunotherapy

    Loss of the HLA locus impairs presentation of tumor antigens and is frequently found in advanced cancers. This talk will describe the landscape of HLA loss and other response biomarkers in a dataset of 90,000 solid tumor samples and highlight the effect of HLA loss on checkpoint inhibitor response.


    Lee A Albacker, PhD
    Director, Cancer Genomics Research, Foundation Medicine

  • 2:35 pm

  • Conference Concludes